fingolimod sold brand name gilenya immunomodulating medication mostly used treating multiple sclerosis fingolimod receptor modulator sequesters lymphocytes lymph nodes preventing contributing autoimmune reaction reported reduce rate relapses relapsingremitting multiple sclerosis approximately onehalf twoyear fingolimod used treatment relapsing form multiple sclerosis effect primary progressive ms clear may also used chronic inflammatory demyelinating common side effects fingolimod head coldsvague increased gammaglutamyl transfer diarrhea nausea abdominal pain fatigue cases skin cancer reported also reported patients taking natalizumab tysabri approved ms fingolimod also associated potentially fatal infections bradycardia case hemorrhaging focal encephalitis inflammation brain two people died one due brain herpes infection second one due herpes zoster unclear whether drug responsible least three cases progressive multifocal leukoencephalopathy also occurred fingolimod also known cause macular edema resulting decreased therefore frequent surveillance eye examinations required taking medication united states fingolimod must dispensed medication guide contains important information uses serious risks include slowing heart rate especially first fingolimod may increase risk serious patients monitored infection treatment two months discontinuation rare brain infection usually leads death severe disability called progressive multifocal leukoencephalopathy pml reported patients treated pml cases usually occur patients weakened immune fingolimod cause vision may increase risk swelling narrowing blood vessels brain posterior reversible encephalopathy serious risks include respiratory problems liver injury increased blood pressure skin fingolimod may cause harm developing fetus health care professionals advise women childbearing age potential risk fetus use effective european medicines agency ema stated multiple sclerosis medicine fingolimod gilenya must used pregnant women women able children using effective derived myriocin metabolite fungus isaria sinclairii structural analogue sphingosine phosphorylated sphingosine kinases cell importantly sphingosine kinase molecular biology phosphofingolimod thought lie activity one five receptors phosphofingolimod causes internalization receptors sequesters lymphocytes lymph nodes preventing moving central nervous system causing relapse multiple sclerosis unphosphorylated moiety fingolimod predominant form drug body also active molecule unphosphorylated fingolimod impairs ability cytotoxic cells kill target cells different mechanism involves arachidonic acid pathway unrelated sphingosine phosphate implications increasing susceptibility viral infections well enhancing therapeutic efficacy multiple additionally fingolimod shifts macrophages antiinflammatory phenotype modulates proliferation morphology cytokine release via inhibition transient receptor potential cation channel subfamily member finally fingolimod also found molecular targets functions fingolimod reported cannabinoid receptor ceramide synthase also reported stimulate repair process glial cells glial precursor cells first synthesized yoshitomi pharmaceuticals fingolimod derived immunosuppressive natural product myriocin ispi chemical modification myriocin isolated culture broth type entomopathogenic fungus isaria sinclairii eternal youth nostrum traditional chinese showing positive results vitro mixed lymphocyte reaction vivo screening prolonging rat skin graft survival time myriocin modified series steps yield fingolimod code named time recent review highlights synthetic methods mode action potential applications structure activity relationship sar studies myriocin homologs partially synthetic derivatives showed configuration carbon bearing group bond group important activity simplification structure ispi done attempt reduce toxicity improve drug elimination side chain functionalities removal chiral centers part simplification process intermediate compound carboxylic acid myriocin transformed hydroxymethyl group generated found less toxic effective lengthening rat skin allograft time september fingolimod became first oral diseasemodifying drug approved us food drug administration fda reduce relapses delay disability progression patients relapsing forms multiple april novartis said drug would available canadian march european medicines agency approved drug use european systematic review concluded treatment people relapsingremitting ms effective reducing probability acute inflammatory relapses potentially little effect disability progression compared riskbenefit profile compared diseasemodifiying therapies unclear due lack direct december generic fingolimod approved united states treatment relapsing forms multiple sclerosis ms fda granted approvals generic fingolimod applications hec pharm co limited biocon limited sun pharmaceutical industries july fingolimod received fast approval use challenge us patent trademark office generic competitor patent office quashed novartiss patent claims stating obvious novartis appealed federal circuit upheld patent office decision april leaving high likelihood generics coming market january panel judges court appeal federal circuit called question validity last remaining orange book patent protecting october supreme court turned request novartis block launch generic versions gilenya united april us supreme court declined hear novartiss request revive key patent gilenya invalidated lower clinical trials ongoing prevent neuropathic pain patients breast cancer treated recently fingolimod molecule incorporated mrna delivery vehicles increase targeting lymphocytes expressing receptor preclinical httpsenwikipediaorgwikifingolimod